<DOC>
	<DOCNO>NCT00001019</DOCNO>
	<brief_summary>Part A : To compare safety immunogenicity two dose level gp120 ( CHO ) MF59 emulsion alone MTP-PE/MF59 adjuvant , administer 0 , 1 , 6 month . Part B : To evaluate safety immunogenicity gp120 MF59 administer five monthly injection . One experimental AIDS vaccine gp120 vaccine . The HIV envelope glycoprotein 120 manufacture recombinant DNA technology use immunogen . Antibodies direct gp120 neutralize HIV-1 , gp120 also stimulate certain type cell-mediated immune response . Because many immunogen , include candidate HIV vaccine , may evoke relatively weak immune response , use adjuvant , substance augment immune response vaccine , interest . MTP-PE/MF59 , compose immunomodulator MTP-PE combine MF59 emulsion , appear promise adjuvant select study gp120 vaccine .</brief_summary>
	<brief_title>Safety Immune Response HIV Vaccine ( SF-2 gp120 ) With Without MTP-PE/MF59 Adjuvant</brief_title>
	<detailed_description>One experimental AIDS vaccine gp120 vaccine . The HIV envelope glycoprotein 120 manufacture recombinant DNA technology use immunogen . Antibodies direct gp120 neutralize HIV-1 , gp120 also stimulate certain type cell-mediated immune response . Because many immunogen , include candidate HIV vaccine , may evoke relatively weak immune response , use adjuvant , substance augment immune response vaccine , interest . MTP-PE/MF59 , compose immunomodulator MTP-PE combine MF59 emulsion , appear promise adjuvant select study gp120 vaccine . In Part A , 32 volunteer ( eight four treatment arm ) randomize receive one two dos ( 15 50 mcg ) gp120 vaccine either MTP-PE/MF59 adjuvant emulsion MF59 emulsion alone . The volunteer receive three IM injection 0 , 1 , 6 month . In Part B , 16 female volunteer ( eight two treatment arm ) randomize receive either MF59 emulsion alone ( placebo ) MF59 emulsion plus gp120 vaccine ( 50 mcg ) . Volunteers receive five IM injection monthly interval .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<mesh_term>Mifamurtide</mesh_term>
	<criteria>Inclusion Criteria Patients must : Normal history physical exam . No identifiable highrisk behavior HIV infection . Negative ELISA HIV . Normal cellmediated immune response use Merieux skin test . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Significant evidence depression . Positive syphilis serology ( e.g. , RPR ) document false positive remote ( &gt; 6 month ) treat infection . Circulating Hepatitis B antigenemia . More two sexual partner , sexual contact highrisk partner , within past 6 month . Patients follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease , use immunosuppressive medication . Significant evidence depression treatment psychiatric problem within past year . History anaphylaxis adverse vaccine reaction . Syphilis , gonorrhea , sexually transmit disease ( include chlamydia pelvic inflammatory disease ) within past 6 month . Prior Medication : Excluded : Immunoglobulin vaccine within past 2 month . Experimental agent within past 30 day . Prior Treatment : Excluded : Blood transfusion cryoprecipitates within past 3 month . Risk Behavior : Excluded : History IV drug use within past year . More two sexual partner , sexual contact highrisk partner , within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>